Skip to content

Amylyx 制药

US · AMLX #2392 按市值排名 上市于 2022
26.34 -1.31 -4.74%
实时 - 追踪5344个代码 - 心跳于272秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了2家。
  • 机构持股总比例下降了14.9个百分点。

机构持股

机构持股比例
91.78% -14.89pp
机构数量
237 -2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund52.37%
Hedge Fund20.04%
VC/PE Fund13.50%
Individual/Insider6.08%
Public Company4.50%
Private Company0.92%
Government Pension Fund0.23%
Sovereign Wealth Fund0.13%
Other2.17%

主要股东 截至 2026-06-30

FMR 13.33% · 16.73M 股
BlackRock 7.03% · 8.83M 股
Perceptive Advisors LLC 6.64% · 8.33M 股
TCG Crossover Management, LLC 4.97% · 6.24M 股
Commodore Capital LP 4.50% · 5.65M 股
Janus Henderson Group plc 4.17% · 5.24M 股
Vanguard Capital Management, LLC 3.86% · 4.85M 股
Saturn V Capital Management LP 3.68% · 4.62M 股
Joshua Cohen 2.51% · 3.15M 股
Justin Klee 2.51% · 3.15M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 24次买入 · 26次卖出

姓名职务持股比例
Joshua Cohen Co-Chief Executive Officer 2.51%
Justin Klee Co-Chief Executive Officer 2.51%
George Milne Independent Chairperson 0.65%
James Frates Chief Financial Officer 0.18%
Karen Firestone Independent Director 0.09%
Camille Bedrosian Chief Medical Officer 0.08%
Gina Mazzariello Chief Legal Officer & General Counsel 0.04%
Bernhardt G. Zeiher Director 0.01%
Daphne Quimi Independent Director 0.00%
Paul Fonteyne Independent Director 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-09 James Frates Chief Financial Officer Private Disposition -1,042 $33.23
2026-09-09 James Frates Chief Financial Officer Open Market Disposition -9,768 $32.27
2026-09-09 Camille Bedrosian Chief Medical Officer Private Disposition -2,081 $33.09
2026-09-09 Camille Bedrosian Chief Medical Officer Open Market Disposition -7,947 $32.21
2026-09-09 Joshua Cohen Co-Chief Executive Officer Private Disposition -919 $33.15
2026-09-09 Joshua Cohen Co-Chief Executive Officer Open Market Disposition -29,545 $32.16
2026-09-09 Justin Klee Co-Chief Executive Officer Private Disposition -1,439 $33.16
2026-09-09 Justin Klee Co-Chief Executive Officer Open Market Disposition -29,025 $32.13
2026-09-09 Gina Mazzariello Chief Legal Officer & General Counsel Private Disposition -11 $33.34
2026-09-09 Gina Mazzariello Chief Legal Officer & General Counsel Open Market Disposition -9,525 $32.46
2026-08-30 Karen Firestone Independent Director Derivative Exercise and Retained +50,000 $1.76–5.05
2026-08-17 James Frates Chief Financial Officer Other Acquisition +22,807 --
2026-08-17 Camille Bedrosian Chief Medical Officer Other Acquisition +22,807 --
2026-08-17 Joshua Cohen Co-Chief Executive Officer Other Acquisition +60,039 --
2026-08-17 Justin Klee Co-Chief Executive Officer Other Acquisition +60,039 --
2026-08-17 Gina Mazzariello Chief Legal Officer & General Counsel Other Acquisition +21,284 --
2026-07-09 Gina Mazzariello Chief Legal Officer & General Counsel Open Market Disposition -30,000 $17.61–18.32
2026-07-08 Gina Mazzariello Chief Legal Officer & General Counsel Intent to Sell (Form 144) -30,000 $17.88
2026-06-03 George Milne Independent Chairperson Other Derivative Acquisition +24,372 $14.31
2026-06-03 Karen Firestone Independent Director Other Derivative Acquisition +24,372 $14.31

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:16 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Amylyx 制药 讨论区 0 条评论

发表评论